Kevin Slawin

This inventor holds 15 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Bellicum Pharmaceuticals, Inc., Baylor College of Medicine, Bellicum Pharmaceutics, Inc.. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Slawin. Retrieved from https://idiyas.com/inventor/kevin-slawin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 9)

% Patents Active = 93.3

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 3.4

ph-index = 8

Forward Citations = 189(Granted Patents)

Company Filing History:

6 out of 9

Bellicum Pharmaceuticals, Inc.

patents

5 out of 618

Baylor College of Medicine

patents

1 out of 1

Bellicum Pharmaceutics, Inc.

patent

4. 1 out of 29

Hybritech Incorporated

patents

5. 2 out of 834,513

Other

patents

Years Active: 2002-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11839647 - Methods for inducing partial apoptosis using caspase polypeptides (2023-12-12),

2. 10934346 - Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 (2021-03-02),

3. 10918705 - Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides (2021-02-16),

4. 10888608 - Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides (2021-01-12),

5. 10525110 - Methods for inducing partial apoptosis using caspase polypeptides (2020-01-07),

6. 10420824 - Induced activation in dendritic cells (2019-09-24),

7. 9944690 - Methods for controlling T cell proliferation (2018-04-17),

8. 9913882 - Methods for inducing partial apoptosis using caspase polypeptides (2018-03-13),

9. 9572835 - Induced activation in dendritic cells (2017-02-21),

10. 8999949 - Induced activation in dendritic cells (2015-04-07),

11. 8771671 - Induced activation in dendritic cells (2014-07-08),

12. 7404950 - Induced activation in dendritic cell (2008-07-29),

13. 6482599 - Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such (2002-11-19),

14. 6479263 - Method for detection of micrometastatic prostate cancer (2002-11-12),

15. 6423503 - Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone (2002-07-23),

Title: Inventor Kevin Slawin

Introduction: Kevin Slawin is a renowned inventor based in Houston, Texas, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Kevin Slawin holds several patents in the areas of medical devices, renewable energy technologies, and consumer electronics, showcasing his diverse range of expertise and interests.

Career Highlights: With a career spanning over two decades, Kevin Slawin has established himself as a prolific inventor with a keen eye for identifying gaps in the market and developing unique solutions to address them. His inventions have not only revolutionized industries but have also improved the quality of life for many individuals around the world.

Collaborations: Throughout his career, Kevin Slawin has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: In conclusion, Kevin Slawin's passion for innovation and his dedication to creating impactful solutions have solidified his reputation as a visionary inventor. His continued pursuit of excellence is sure to lead to many more groundbreaking inventions in the future.

Profile summary based on public USPTO records.